menu
    • menu

    Company profile for GSK

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At GSK we have a challenging mission: to improve the quality of human life by enabling people to do more, feel better, live longer. Find out how this shapes everything we do, including our R&D, our partnerships, our work with communities and our efforts to prevent and treat disease around the world. We are a science-led global healthcare company with a mission: we want to help people to do more, feel better, live longer. The...
    At GSK we have a challenging mission: to improve the quality of human life by enabling people to do more, feel better, live longer. Find out how this shapes everything we do, including our R&D, our partnerships, our work with communities and our efforts to prevent and treat disease around the world. We are a science-led global healthcare company with a mission: we want to help people to do more, feel better, live longer. The vaccines, medicines and consumer healthcare products that we research and develop can improve people’s health and well-being, ultimately helping them to live life to its fullest and contribute.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GSKunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    980 Great West Road, Brentford, Middlesex TW8 9GS England
    Telephone
    Telephone
    +44 (0)20 8047 5000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gsk.com:443/en-gb/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI WW Frankfurt

    Not Confirmed

    envelop Contact Supplier

    CPhI WW Frankfurt

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    "50 Years of Innovation: Mikart

    mic"50 Years of Innovation: Mikart's legacy and what's next in CDMO excellence"

    This week, SpeakPharma interviews Michael Kallelis, CEO of Mikart, a leading contract development and manufacturing organization (CDMO) celebrating its 50th anniversary in the pharmaceutical industry. Based in the United States, Mikart has built a reputation for technical expertise, flexible business terms, and specialized capabilities in pharmaceutical development services. In this exclusive interview, Kallelis discusses how Mikart maintains its competitive edge through its Pharmaceutical Development Services team, quality control framework, and commitment to customized business solutions. Kallelis also explores the company's focus on liquid suspensions manufacturing, driven by growing demand from aging populations and pediatric patients, and explains how Mikart balances traditional family business values with modern innovation. HIGHLIGHTS// celebrating its 50th anniversary/ reputation for technical expertise/ how Mikart maintains its competitive edge Mikart is celebrating 50 years in business this year — what are some of the major milestones that have shaped the company's journey?  Over our 50-year history, we've celebrated many memorable milestones, but one of the most significant in recent years has been achieving our growth objectives. This success was driven by the strategic expansion of our Pharmaceutical Development Services team, the completion of full aggregate serialization in our packaging department, modernization of our IT systems, enhanced productivity, and our ability to attract both new and returning customers. HIGHLIGHTS// expansion of our Pharmaceutical Development Services team/ completion of full aggregate serialization/ attract both new and returning customers How has Mikart maintained its competitive edge in a constantly evolving pharmaceutical landscape? Our customers consistently tell us that what sets us apart is our technical expertise, high service level, and flexible, customized business terms. At the core of our competitiveness is our focus on Pharmaceutical Development Services (PDS). Mikart's PDS opinion leaders are actively engaged in business development and form early, collaborative relationships with our customers' technical teams. From the outset, our prospects and clients work directly with Mikart's experienced formulation chemists, analytical method developers, and process-oriented engineers to design robust, reproducible, and efficient processes. This hands-on development approach is supported by a comprehensive quality control testing framework — covering raw material testing, in-process checks, on-site microbiological testing, and in-house stability studies. Oversight is provided by our robust Quality Management System, managed by a dedicated Quality Assurance and Regulatory Affairs team. The result is disciplined problem-solving, timely FDA submissions, and a "right-first-time" philosophy that accelerates time-to-market. We operate with a strong sense of urgency and consistently deliver a high level of customer satisfaction. What truly differentiates Mikart is our commitment to customized business terms that eliminate common roadblocks seen with other CDMOs. Our secret sauce is our exceptional service and flexibility in helping our customers bring innovative medicines to patients. HIGHLIGHTS// technical expertise, high service level/ flexible, customized business terms/ comprehensive quality control testing framework/ dedicated Quality Assurance and Regulatory Affairs team/ timely FDA submissions/ accelerates time-to-market What capabilities or services does Mikart offer today that didn't exist 10 or 20 years ago? Mikart was an early leader in serialization, implementing full capabilities well ahead of the industry timeline. This proactive approach has kept our packaging team in high demand. We also upgraded our tablet compression equipment to enhance both speed and reliability. To support growing development needs, we invested in new lab-scale development equipment, unit dose cup filling, sachet packaging, low-humidity suites, and a brand-new suite dedicated to closed-system manufacturing of liquids and suspensions. Most recently, we launched a multi-million dollar expansion of our packaging lines to support higher-speed tablet filling, powder-in-bottle formats, and new liquid fill capabilities. HIGHLIGHTS// early leader in serialization/ upgraded our tablet compression equipment/ multi-million dollar expansion of our packaging lines Why are liquid suspensions becoming such a key focus, and how is Mikart positioned? Formulating suspensions is a complex process that requires specialized expertise and equipment. According to our customers, few mid-market CDMOs do it well — and Mikart is one of them. There is growing industry demand for high-quality suspension manufacturing, driven by the needs of the aging baby boomer population and pediatric patients. For both groups, swallowing tablets or capsules can be difficult, making oral liquid suspensions a more practical alternative. In addition to being easier to administer, suspensions offer pharmacological advantages and can improve dosing compliance. Enhanced flavoring techniques further improve the patient experience — especially for children and infants — by making medicines more palatable. HIGHLIGHTS// growing industry demand for high-quality suspension manufacturing/ suspensions offer pharmacological advantages/ improve dosing compliance How does Mikart balance tradition with innovation to meet modern customer demands?  At Mikart, we work hard to preserve the values of a traditional family business, even as we continue to modernize. Our goal is to make every customer feel like they are our top priority. Each customer is supported by a dedicated project manager who serves as their primary point of contact, along with direct access to key team members across departments. This structure ensures our customers are never isolated from our subject matter experts and can get timely, accurate answers to their questions. We're also mindful of the "technology trap" — the tendency to pursue every new innovation at the expense of focus and efficiency. Instead, we rely on market data and customer trends to guide our investments, enabling us to concentrate our resources and capital on technologies that meet real market needs. HIGHLIGHTS// customer is supported by a dedicated project manager/ customers are never isolated from our subject matter experts/ we rely on market data and customer trends to guide our investments/ meet real market needs Looking ahead, what's in store for Mikart in the next 5-10 years? Mikart's strategic plan is now in full motion, and with the momentum we've built, 50 percent growth is within reach. This projection is backed by a strong pipeline of annual FDA filings, a growing customer base, and a robust portfolio of active Pharmaceutical Development Services projects. As we grow, we remain committed to delivering exceptional service and continuously evolving to meet the changing needs of our customers. With renewed political emphasis on domestic manufacturing for the US market, we are ideally positioned to support the rapid, cost-effective development and production of high-quality medicines here at home. As we approach our 50th anniversary in the CDMO industry, we celebrate our legacy and look forward with optimism to the opportunities ahead in the next 5 to 10 years. HIGHLIGHTS// 50 percent growth is within reach/ strong pipeline of annual FDA filings 

    Impressions: 2712

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence

    PharmaCompass
    17 Jul 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaIngredients for Innovative FormulationsIngredients for Innovative Formulations

    Ingredients for Innovative Formulations
    Ingredients for Innovative Formulations

    reelIngredients for Innovative Formulations

    This PharmaReel highlights Kirsch Pharma’s expertise in providing premium quality raw materials, custom blends, and tailor-made solutions. With 40+ years of expertise and certified quality (GMP, ISO 9001, FSSC 22000, Halal, Kosher), Kirsch supports pharma, biotech, and nutrition industries worldwide.

    Impressions: 646

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    FDA approvals drop 24% in H1 2025; GSK’s UTI med, Vertex’s non-opioid painkiller lead pack of first-in-class meds

    FDA approvals drop 24% in H1 2025; GSK’s UTI med, Vertex’s non-opioid painkiller lead pack of first-in-class meds

    It has been a turbulent year for the US Food and Drug Administration (FDA), marked by reductions in both staff and budget, shake-ups at the top and a reduction in inspections. This upheaval has clearly impacted the functioning of the agency, with reports of missed deadlines and reduced responsiveness. This disruption resulted in a slowdown in new drug approvals in the first half of 2025 (H1 2025), as opposed to the same period last year. Incidentally, drug approvals in H1 2024 were also down by 19 percent compared to H1 2023. FDA’s Center for Drug Evaluation and Research (CDER) approved 16 novel drugs in H1 2025, down from 21 in H1 2024, a decline of nearly 24 percent. Of these, nine were small molecules and seven were biologics. The period saw eight first-in-class therapies get CDER’s approval, as opposed to 17 in H1 2024. FDA’s Center for Biologics Evaluation and Research (CBER) approved seven biologics in H1 2025, compared to eight in the same period last year. In comparison, both Health Canada and the European Medicines Agency (EMA) reported a strong rebound in approvals and authorizations, respectively. Health Canada approved 20 drugs in H1 2025, as opposed to 10 in H1 2024. Similarly, EMA authorized 19 new therapies in H1 2025, compared to 15 in H1 2024. Notably, EMA’s pending decisions increased to 25 in H1 2025, from 14 in the same period last year, while conditional authorizations remained static at five. This underscores EMA’s active regulatory pipeline, suggesting that more drugs could be approved in Europe soon.   View New Drug Approvals in H1 2025 with Estimated Sales (Free Excel Available) Vertex’s non-opioid painkiller, GSK’s antibiotic for UTI, Merck’s RSV antibody bag FDA nods Oncology remained the single largest category in H1 2025 with seven new drugs being approved by the FDA, followed by four rare diseases and disorders and as many infections and infective diseases.  The eight drugs that were designated first-in-class in H1 2025 are: Journavx (Suzetrigine), Imaavy (nipocalimab), Emrelis (telisotuzumab vedotin), Blujepa (gepotidacin mesylate), Qfitlia (fitusiran), Avmapki Fakzynja Co-Pack (avutometinib potassium/defactinib hydrochloride), Tryptyr (acoltremon), and Andembry (garadacimab). In January, a new class of non-opioid pain therapy made a debut — FDA approved Vertex Pharmaceuticals’ Journavx (suzetrigine). This first-in-class oral analgesic could bring in US$ 2.9 billion in sales for Vertex by 2030. The half year also saw a new oral antibiotic — GSK’s Blujepa (gepotidacin) — for treating uncomplicated urinary tract infections (uUTIs) bag FDA approval. This is the first new antibiotic for uUTIs in nearly three decades. It treats infections caused by resistant pathogens such as E. coli and K. pneumoniae. In June, Merck’s Enflonsia (clesrovimab), a long-acting monoclonal antibody, won FDA approval to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season. A single 105 mg dose provides protection for about five months, the length of a typical RSV season. Enflonsia could bring in US$844 million in annual sales by 2030.   View New Drug Approvals in H1 2025 with Estimated Sales (Free Excel Available)  FDA approves four meds for rare diseases, including SpringWorks’ Gomekli, Novartis’ Vanrafia In H1 2024, rare genetic diseases had witnessed some significant approvals. The trend continued in H1 2025. In February, Gomekli (mirdametinib), developed by SpringWorks Therapeutics, became the first approved therapy for neurofibromatosis type 1 (a genetic disorder that causes tumors to grow on nerve tissues) in adult and pediatric patients who have symptomatic plexiform neurofibromas (benign, complex nerve tumors) not amenable to complete resection. Analysts expect peak sales of around US$ 0.8 billion by 2030. Post this approval, SpringWorks got acquired by Merck KGaA for approximately US$ 3.9 billion. The same month, Ono Pharma-owned Deciphera’s Romvimza (vimseltinib) became the first oral therapy approved for another rare disease known as symptomatic tenosynovial giant cell tumor. This is a benign but aggressive growth that can be painful. This new drug offers patients an option beyond surgery. In March, Sanofi’s Qfitlia (fitusiran) was approved for routine prophylaxis in hemophilia A or B, with or without inhibitors. And in April, Novartis’ Vanrafia (atrasentan) was granted accelerated approval for IgA nephropathy (a chronic autoimmune kidney disease), which is at the risk of rapid progression. Vanrafia could bring in sales of over US$ 735 million by 2030. Johnson & Johnson secured approval for Imaavy (nipocalimab-aahu) for generalized myasthenia gravis (a chronic autoimmune disease that causes muscle weakness) in adults and adolescents. Imaavy’s sales could cross US$1.17 billion by 2030. Rare diseases continue to attract regulatory attention, with the trend carrying into the current quarter. July witnessed two noteworthy rare-disease approvals — Ekterly (garadacimab), CSL’s once-monthly prophylactic treatment for hereditary angioedema (a genetic disorder that causes recurrent episodes of swellings), and Sephience (pegvaliase-abcx), BioMarin’s new therapy for phenylketonuria (a rare metabolic disorder).   View New Drug Approvals in H1 2025 with Estimated Sales (Free Excel Available)  FDA greenlights new oncology therapies, including Astra’s Datroway, AbbVie’s Emrelis The field of oncology saw some notable new drug approvals. In January, Datroway (datopotamab deruxtecan), an antibody-drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo, was granted approval for adults with unresectable or metastatic, hormone receptor-positive, HER2-negative breast cancer. Later, in June, the FDA granted accelerated approval  to AstraZeneca;s Datroway for adults with locally advanced or metastatic, EGFR-mutated non-small cell lung cancer. The drug’s peak annual sales are projected at about US$ 4.2 billion by 2030. In May, Emrelis (telisotuzumab vedotin-tllv), AbbVie’s ADC was granted FDA’s accelerated approval. Emrelis treats locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) characterized by significantly increased levels of the c-Met protein in cancer cells. FDA also approved a companion diagnostic test — Roche's Ventana — in May to determine the c-Met protein biomarker status in order to identify patients eligible for Emrelis.  The same month, FDA also granted accelerated approval to Verastem’s Avmapki Fakzynja Co-pack, a dual oral therapy for adults with KRAS‑mutated recurrent low‑grade serous ovarian cancer (LGSOC). This novel regimen combines two inhibitors — avutometinib and defactinib — to disrupt critical signaling pathways that fuel tumor growth. In ophthalmology, Alcon re-entered the prescription pharmaceutical market with Tryptry (acoltremon), a first-in-class TRPM8 agonist for dry eye disease, which stimulates corneal nerves to increase tear production.   View New Drug Approvals in H1 2025 with Estimated Sales (Free Excel Available)  Our view The changes in the FDA are clearly having a far-reaching impact on the global pharmaceutical industry. There have been reports of drugmakers losing confidence in the FDA, which has been a gold standard for drug regulation. Some American biotechs are shifting early trials outside of the US. With EMA and Health Canada authorizing/approving a larger number of drugs in H1 2025, we do see some changes underway that may eventually reshape drug development.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4838

    https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds

    #PharmaFlow by PHARMACOMPASS
    28 Aug 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    GSK Adds Moderna's Next-Gen Covid Shot to MRNA Patent Lawsuit
    GSK Adds Moderna's Next-Gen Covid Shot to MRNA Patent Lawsuit

    05 Sep 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/seeking-royalties-gsk-expands-mrna-patent-litigation-include-modernas-next-generation-covid

    FIERCE PHARMA
    05 Sep 2025
    Share Share
    GSK forays into oncology in India with Jemperli and Zejula
    GSK forays into oncology in India with Jemperli and Zejula

    25 Aug 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/gsk-forays-into-oncology-in-india-with-jemperli-and-zejula-17655

    INDPHARMAPOST
    25 Aug 2025
    Share Share
    Iterum Pursues Dual-Track Strategy for First UTI Drug in 25 Years
    Iterum Pursues Dual-Track Strategy for First UTI Drug in 25 Years

    20 Aug 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/breaking-down-dual-track-strategy-behind-iterums-launch-first-new-uncomplicated-uti-drug

    FIERCE PHARMA
    20 Aug 2025
    Share Share
    GSK's Gepotidacin Gets Priority Review from U.S. FDA
    GSK's Gepotidacin Gets Priority Review from U.S. FDA

    11 Aug 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/gsks-gepotidacin-granted-priority-review-by-u-s-fda/

    CONTRACTPHARMA
    11 Aug 2025
    Share Share
    GSK Pharma Q1 PAT rises 12% to 279 cr, income marginally down
    GSK Pharma Q1 PAT rises 12% to 279 cr, income marginally down

    01 Aug 2025

    // BUSINESS STD

    https://www.business-standard.com/companies/quarterly-results/gsk-pharma-q1-results-pat-rises-12-to-279-cr-income-declines-marginally-125080101055_1.html

    BUSINESS STD
    01 Aug 2025
    Share Share
    GSK Holds to Its £40B Projection for 2031, Despite Blenrep Woes
    GSK Holds to Its £40B Projection for 2031, Despite Blenrep Woes

    31 Jul 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/despite-blenrep-uncertainty-gsk-sticks-its-ps40b-projection-2031

    FIERCE PHARMA
    31 Jul 2025
    Share Share

    FDA Orange Book

    read-more
    read-more

    South Africa

    read-more
    read-more

    01

    Brand Name : Fluarix Tetra

    United Kingdom
    ChemOutsourcing
    Not Confirmed
    arrow

    Brand Name : Fluarix Tetra

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    A/HongKong/K4801/2014 (H3N2)

    GSK

    Dosage Form : INJ

    Dosage Strength : 15ug

    Packaging : 0.5X1ug

    Brand Name : Fluarix Tetra

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Fluarix Tetra

    United Kingdom
    ChemOutsourcing
    Not Confirmed
    arrow

    Brand Name : Fluarix Tetra

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    A/Michigan/45/2015 (H1N1) PDM09

    GSK

    Dosage Form : INJ

    Dosage Strength : 15ug

    Packaging : 0.5X1ug

    Brand Name : Fluarix Tetra

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Trizivar

    United Kingdom
    ChemOutsourcing
    Not Confirmed
    arrow

    Brand Name : Trizivar

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Abacavir

    GSK

    Dosage Form : TAB

    Dosage Strength : 300mg

    Packaging : 60X1mg

    Brand Name : Trizivar

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Kivexa

    United Kingdom
    ChemOutsourcing
    Not Confirmed
    arrow

    Brand Name : Kivexa

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Abacavir

    GSK

    Dosage Form : TAB

    Dosage Strength : 600mg

    Packaging : 30X1mg

    Brand Name : Kivexa

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Trelavue

    United Kingdom
    ChemOutsourcing
    Not Confirmed
    arrow

    Brand Name : Trelavue

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Abacavir

    GSK

    Dosage Form : TAB

    Dosage Strength : 600mg

    Packaging : 30X1mg

    Brand Name : Trelavue

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Ziagen Tablets

    United Kingdom
    ChemOutsourcing
    Not Confirmed
    arrow

    Brand Name : Ziagen Tablets

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Abacavir

    GSK

    Dosage Form : TAB

    Dosage Strength : 300mg

    Packaging : 60X1mg

    Brand Name : Ziagen Tablets

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Ziagen Oral Solution

    United Kingdom
    ChemOutsourcing
    Not Confirmed
    arrow

    Brand Name : Ziagen Oral Solution

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Abacavir

    GSK

    Dosage Form : SYR

    Dosage Strength : 20mg/ml

    Packaging : 240X1mg/ml

    Brand Name : Ziagen Oral Solution

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Zovirax

    United Kingdom
    ChemOutsourcing
    Not Confirmed
    arrow

    Brand Name : Zovirax

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Aciclovir

    GSK

    Dosage Form : OIN

    Dosage Strength : 30mg/g

    Packaging : 4.5X1mg/g

    Brand Name : Zovirax

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Zovirax IV

    United Kingdom
    ChemOutsourcing
    Not Confirmed
    arrow

    Brand Name : Zovirax IV

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Aciclovir

    GSK

    Dosage Form : INJ

    Dosage Strength : 250mg

    Packaging : 10X5mg

    Brand Name : Zovirax IV

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Zovirax Suspension

    United Kingdom
    ChemOutsourcing
    Not Confirmed
    arrow

    Brand Name : Zovirax Suspension

    United Kingdom
    arrow
    ChemOutsourcing
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Originator

    Registration Country : South Africa

    Aciclovir

    GSK

    Dosage Form : SUS

    Dosage Strength : 200mg/5ml

    Packaging : 125X1mg/5ml

    Brand Name : Zovirax Suspension

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact GSK and get a quotation

    GSK is a supplier offers 142 products (APIs, Excipients or Intermediates).

    Find a price of Cefuroxime Sodium bulk with DMF, CEP offered by GSK

    Find a price of Fluticasone Propionate bulk with DMF, CEP offered by GSK

    Find a price of Amoxicillin Trihydrate bulk with CEP offered by GSK

    Find a price of Betamethasone Valerate bulk with CEP offered by GSK

    Find a price of Ceftazidime bulk with CEP offered by GSK

    Find a price of Clavulanic Acid bulk with CEP offered by GSK

    Find a price of Clobetasol Propionate bulk with CEP offered by GSK

    Find a price of Salbutamol Sulphate bulk with CEP offered by GSK

    Find a price of Ceftazidime bulk with DMF offered by GSK

    Find a price of Cefuroxime Axetil bulk offered by GSK

    Find a price of Clavulanic Acid bulk offered by GSK

    Find a price of Fluticasone Furoate bulk with DMF offered by GSK

    Find a price of Fluticasone Propionate bulk with DMF offered by GSK

    Find a price of Griseofulvin bulk offered by GSK

    Find a price of Labetalol Hydrochloride bulk offered by GSK

    Find a price of Mupirocin Calcium bulk offered by GSK

    Find a price of Paroxetine Hydrochloride bulk with DMF offered by GSK

    Find a price of Salbutamol Sulphate bulk with DMF offered by GSK

    Find a price of Salmeterol Xinafoate bulk with DMF offered by GSK

    Find a price of Umeclidinium Bromide bulk with DMF offered by GSK

    Find a price of Vilanterol Trifenatate bulk with DMF offered by GSK

    Find a price of Live attenuated mumps bulk bulk with JDMF offered by GSK

    Find a price of 6-Aminopenicillanic Acid bulk offered by GSK

    Find a price of Albendazole bulk offered by GSK

    Find a price of Amoxicillin Sodium bulk offered by GSK

    Find a price of Amoxicillin Trihydrate bulk offered by GSK

    Find a price of Ampicillin bulk offered by GSK

    Find a price of Ampicillin Sodium bulk offered by GSK

    Find a price of Ampicillin Trihydrate bulk offered by GSK

    Find a price of Auranofin bulk offered by GSK

    Find a price of Beclomethasone Dipropionate bulk offered by GSK

    Find a price of Betamethasone Dipropionate bulk offered by GSK

    Find a price of Betamethasone Valerate bulk offered by GSK

    Find a price of Calcitonin bulk offered by GSK

    Find a price of Caramiphen Ethanedisulfonate bulk offered by GSK

    Find a price of Carbenicillin Indanyl bulk offered by GSK

    Find a price of Cephalexin bulk offered by GSK

    Find a price of Cephalosporin bulk offered by GSK

    Find a price of Cephradine bulk offered by GSK

    Find a price of Chlorpheniramine Maleate bulk offered by GSK

    Find a price of Cimetidine bulk offered by GSK

    Find a price of Clobetasol Propionate bulk offered by GSK

    Find a price of Clobetasone Butyrate bulk offered by GSK

    Find a price of Cloxacillin Benzathine bulk offered by GSK

    Find a price of Cloxacillin Sodium bulk offered by GSK

    Find a price of Deoxyuridine bulk offered by GSK

    Find a price of Diethylcarbamazine Citrate bulk offered by GSK

    Find a price of Diphenidol bulk offered by GSK

    Find a price of Diphenylpyraline bulk offered by GSK

    Find a price of Dopamine bulk offered by GSK

    Find a price of Doxepin Hydrochloride bulk offered by GSK

    Find a price of Fondaparinux Sodium bulk offered by GSK

    Find a price of Hydrochlorothiazide bulk offered by GSK

    Find a price of Isopropamide Iodide bulk offered by GSK

    Find a price of Liothyronine Sodium bulk offered by GSK

    Find a price of Megestrol Acetate bulk offered by GSK

    Find a price of Methicillin bulk offered by GSK

    Find a price of Mupirocin bulk offered by GSK

    Find a price of Nafcillin Sodium bulk offered by GSK

    Find a price of Oxacillin Sodium bulk offered by GSK

    Find a price of Paroxetine Hydrochloride bulk offered by GSK

    Find a price of Penicillin G Potassium bulk offered by GSK

    Find a price of Propyliodone bulk offered by GSK

    Find a price of Sodium Dicloxacillin bulk offered by GSK

    Find a price of Streptokinase bulk offered by GSK

    Find a price of Streptomycin bulk offered by GSK

    Find a price of Sucralfate bulk offered by GSK

    Find a price of Tetanus Immunoglobulin bulk offered by GSK

    Find a price of Ticarcillin bulk offered by GSK

    Find a price of Ticarcillin Monosodium bulk offered by GSK

    Find a price of Tranylcypromine Sulfate bulk offered by GSK

    Find a price of Trifluoperazine Hydrochloride bulk offered by GSK

    Find a price of Vitamin B12 bulk offered by GSK

    Find a price of Zidovudine bulk offered by GSK

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GREENVILLE, NORTH CAROLINA. bulk offered by GSK

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND GENERAL OPERATING PROCEDURES IN SINGAPORE bulk offered by GSK

    Find a price of COMPOUND 904 bulk offered by GSK

    Find a price of FACILITIES, METHODS AND CONTROLS bulk offered by GSK

    Find a price of BUILDINGS AND FACILITIES IN SEALS SANDS, ENGLAND bulk offered by GSK

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MONTROSE, ANGEES, SCOTLAND. bulk offered by GSK

    Find a price of BRL 47539 (2-ACETOXYMETHYL-4-IODOBUT-1-YL-ACETATE) bulk offered by GSK

    Find a price of MFG. SITE FACILITIES UTILIZED IN SPEKE LIVERPOOL (UK) bulk offered by GSK

    Find a price of FACILITIES&CONTROLS AT HARLOW AND GREAT BURGH RESEARCH SITES, ENGLAND bulk offered by GSK

    Find a price of ENTRENOL bulk offered by GSK

    Find a price of FACIL, PERSONNEL AND GENERAL OPERATING PROCEDURES IN HARLOW, ESSEX. bulk offered by GSK

    Find a price of FACILITIES & CONTROLS OF THE WELLCOME FOUNDATION IN KENT ENGLAND bulk offered by GSK

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN CAROLINA, PUERTO RICO. bulk offered by GSK

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN CIDRA, PUERTO RICO. bulk offered by GSK

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES. bulk offered by GSK

    Find a price of MFGR, CONTROL PROCEDURES & FACILITIES-MYERSTOWN, PA., PLANT bulk offered by GSK

    Find a price of MANUFACTURING SITE, FACILITIES, PESONNEL, AND GENERAL OPERATING PROCEDURES IN WEST SUSSEX, ENGLAND. bulk offered by GSK

    Find a price of MANUFACTURING SITE AND FACILITIES FOR ANNAN, UK PLANT bulk offered by GSK

    Find a price of FACILITIES AND OPERATING PROCEDURES IN TIANJIN, CHINA bulk offered by GSK

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN CUERNAVACA, MEXICO. bulk offered by GSK

    Find a price of MFG. FACILITIES LOCATED IN JURONG, SINGAPORE bulk offered by GSK

    Find a price of 7-ACA TOSYLATE bulk offered by GSK

    Find a price of PENN CHEMICALS PRODUCTION FACILITY IN COUNTY CORK, IRELAND bulk offered by GSK

    Find a price of FACILITIES AND MANUFACTURING bulk offered by GSK

    Find a price of GENERAL OPERATING PROCEDURES SINGAPORE PLANT bulk offered by GSK

    Find a price of FACIL, PERSONNEL & GENL OPER PROCED IN GREAT BURGH, EPSOM, U.K. bulk offered by GSK

    Find a price of CLENOLIXIMAB [CHIMERIC (MACAQUE/HUMAN) MONOCLONAL ANTIBODY (SB-217969) (CHO CELLS, SMITHKLINE BEECHAM) TO CD4] bulk offered by GSK

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN TONBRIDGE, KENT, ENGLAND. bulk offered by GSK

    Find a price of L-DM1 bulk offered by GSK

    Find a price of ASO1B ADJUVANT SYSTEM bulk offered by GSK

    Find a price of O/4 DIHYDROCHLORIDE DIHYRATE (CPZ ROUTE) bulk offered by GSK

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN BOMBAY, INDIA. bulk offered by GSK

    Find a price of FACILITY IN BUCKHAVEN, UNITED KINGDOM bulk offered by GSK

    Find a price of 0/4 DIHYDROCHLORIDE DIHYDRATE (CEPHALORIDINE ROUTE-CP)-ULVERSTON PLANT bulk offered by GSK

    Find a price of MANUFACTURING FACILITY AT VERONA, ITALY. bulk offered by GSK

    Find a price of FACILITIES UTILIZED IN WARE HERTS, UNITED KINGDOM bulk offered by GSK

    Find a price of FACILS AND GEN OPER PROCEDS AT THE ULVERSTON PLANT bulk offered by GSK

    Find a price of FACILITY LOCATED IN EDINBURG, SCOTLAND bulk offered by GSK

    Find a price of SYNTHESIS & QUALITY CONTROLS FOR 5,7-DICHLORO-8-HYDROXYQUINOLONE bulk offered by GSK

    Find a price of MANUFACTURING PRODUCTION FACILITY IN TORONTO, CANADA bulk offered by GSK

    Find a price of GENERAL OPERATING PROCEDURES FOR THE HEPPIGIES, BELGIUM--ANTIBIOTICS bulk offered by GSK

    Find a price of 'ZENTEL' 'TILTAB' TABLETS bulk offered by GSK

    Find a price of CHIMERIC (MACAQUE VARIABLE/HUMAN CONSTANT) (RECOMBINANT, CHO CELLS) MONOCLONAL ANTIBODY (SB 210396; CE9.1) TO HUMAN CD4 ANTIGEN bulk offered by GSK

    Find a price of HIV VACCINE (GPL 120/NEFTA/ASO2A) bulk offered by GSK

    Find a price of Abacavir Sulfate bulk offered by GSK

    Find a price of Benzyl Penicillin bulk offered by GSK

    Find a price of Cabotegravir bulk offered by GSK

    Find a price of Cabotegravir Sodium bulk offered by GSK

    Find a price of CAS 103639-04-9 bulk offered by GSK

    Find a price of Daprodustat bulk offered by GSK

    Find a price of Dolutegravir Sodium bulk offered by GSK

    Find a price of Dutasteride bulk offered by GSK

    Find a price of Epsiprantel bulk offered by GSK

    Find a price of Fluticasone Furoate bulk offered by GSK

    Find a price of Lacidipine bulk offered by GSK

    Find a price of Lamivudine bulk offered by GSK

    Find a price of Nabumetone bulk offered by GSK

    Find a price of Naratriptan Hydrochloride bulk offered by GSK

    Find a price of Nelarabine bulk offered by GSK

    Find a price of Ondansetron bulk offered by GSK

    Find a price of Pazopanib Hydrochloride bulk offered by GSK

    Find a price of Ranitidine Hydrochloride bulk offered by GSK

    Find a price of Retapamulin bulk offered by GSK

    Find a price of Trametinib bulk offered by GSK

    Find a price of Umeclidinium Bromide bulk offered by GSK

    Find a price of Vilanterol Trifenatate bulk offered by GSK

    Find a price of Zanamivir bulk offered by GSK

    Find a price of MEDICATED FEED bulk offered by GSK

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search